Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 77Breast Neoplasms 53Colorectal Neoplasms 52Neoplasms 40Advanced Solid Tumors 34Prostatic Neoplasms 31Multiple Myeloma 31Ovarian Neoplasms 28Neoplasm Metastasis 28Recurrence 27Lung Neoplasms 27Carcinoma, Hepatocellular 27Pancreatic Neoplasms 26Advanced Solid Tumor 22Small Cell Lung Carcinoma 20Leukemia, Myeloid, Acute 20Melanoma 18Endometrial Neoplasms 18Triple Negative Breast Neoplasms 17Squamous Cell Carcinoma of Head and Neck 14Lymphoma, Follicular 14Stomach Neoplasms 13Lymphoma, B-Cell 13Glioma 13Glioblastoma 13Uterine Cervical Neoplasms 12Lymphoma 11Head and Neck Neoplasms 11Solid Tumor 10Myasthenia Gravis 9

Interventions

trifluridine tipiracil drug combination 1tipiracil 1regorafenib 1Trifluridine 1Tablets 1HMPL-013 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × INDUSTRY × HER2 IHC3+ Advanced Colorectal Cancer × Clear all
NCT07483684 2026-03-19

A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Not yet recruiting
142 enrolled
Gastrointestinal

HER2 IHC3+ Advanced Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡